Cibenzoline-d4

• Description:

  Cibenzoline-d4 (Cifenline-d4) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia[1][2][3][4].

• Product Name Alternative:

  Cifenline-d4; Ro 22-7796-d4

• UNSPSC:

  12352005

• Target:

  Isotope-Labeled Compounds; Potassium Channel

• Related Pathways:

  Membrane Transporter/Ion Channel; Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Cardiovascular Disease

• Smiles:

  [2H]C1([2H])NC(C2CC2(C3=CC=CC=C3)C4=CC=CC=C4)=NC1([2H])[2H]

• Molecular Formula:

  C18H14D4N2

• Molecular Weight:

  266.37

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Mukai E, et al. The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Biochem Biophys Res Commun. 1998;251 (2) :477-481.|[3]Hamada M, et al. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1997;96 (5) :1520-1524.|[4]Satoh H. Comparative actions of cibenzoline and disopyramide on I (Kr) and I (Ks) currents in rat sino-atrial nodal cells. Eur J Pharmacol. 2000 Oct 27;407 (1-2) :123-9.|[5]Takahashi Y, et al. Pharmacodynamics of cibenzoline-induced hypoglycemia in rats. Drug Metab Pharmacokinet. 2011 Jun;26 (3) :242-7.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported